Korea’s Biohealth Exports Reach $7.3 Billion in Q1 2026 Amid Robust Growth

The Korea Health Industry Development Institute announced on the 10th that biohealth exports for Q1 2026 reached $7.3 billion, marking a 14.4% increase compared to the previous year. This performance underscores a stable growth trajectory for the industry, particularly in pharmaceuticals, medical devices, and cosmetics.

Pharmaceutical exports totaled $2.71 billion, an increase of 11.7%, primarily fueled by growing demand for biopharmaceuticals in the European market. This signals a diversification of market reliance, as European countries increasingly turn to Korean biopharmaceutical products, which may enhance long-term revenue channels for manufacturers.

Medical device exports also exhibited growth, reaching $1.46 billion, up 5.6%. Continued demand for ultrasound diagnostic devices and electric medical devices suggests enduring stability in these categories. The increase indicates a potential for expanding market share in major international markets and strengthens the overall competitive positioning of Korean manufacturers.

Cosmetics exports, which reached a record high of $3.13 billion, demonstrated even more vigorous growth, up 21.5% year-over-year. Key contributing factors include rising global demand for K-Beauty products and significant export hikes to the U.S. and U.K. This robust performance illustrates a successful international branding strategy and signals an opportunity for retailers and distributors to capitalize on these favorable demand trends.

The cosmetics segment benefited particularly from the export of skincare products, which accounted for 77.6% of total cosmetic exports, rising to $2.43 billion with a 26.5% increase from the previous year. This gain underlines the critical importance of skincare in the portfolio of beauty retailers, reinforcing the necessity for distributors to align with brands that offer these high-demand products.

Despite the overall positive performance, the makeup sector saw an 8.7% decline, especially due to weak exports to Japan and China. This shift suggests potential volatility in certain product segments, which could inform future investment and inventory strategies for retailers aiming to mitigate risk in these fluctuating areas.

Lee Byung-Kwan, head of the Biohealth Innovation Planning Division, stated on the 10th that despite the typically slow export season at the beginning of the year, the biohealth industry has successfully maintained its growth momentum. The focus on pharmaceuticals and cosmetics highlights the ongoing enhancements in global competitiveness. He emphasized the need for continued monitoring of external market uncertainties to safeguard future export growth.